-
NEWS RELEASE
2021.08.31
COVID-19 is now being recognized as a multi-organ disease that causes not only pneumonia, but also cause damage to other organs such as the liver, kidney and intestines.
-
NEWS RELEASE
2021.08.13
ENYO Pharma (France) announced on 28 July, 2021, positive Vonafexor (EYP001) results for the LIVIFY phase 2a study in F2-F3 NASH patients over 12 weeks.
-
PUBLICATION
National Defense Medical College's publication in Surgery Open Science
2021.08.04
SMC announces that National Defense Medical College (Japan) has published the results of a study using STAM™ mouse model in Surery Open Science.
-
UPDATE
2021.07.20
We recently made a presentation on our STAM™ mouse at the 81st Annual Meeting of the American Diabetes Association (June 25 to 29, 2021).
-
PRODUCTS AND SERVICES
Introducing our new model: Liver Orthotopic Xenograft mouse model
2021.07.01
We’re getting in touch today with an announcement regarding the addition of the Liver Orthotopic Xenograft mouse model to our model line-up – a cancer model that also allows the evaluation of the tumor microenvironment.
-
PUBLICATION
Our clients’ presentations at DDW 2021
2021.06.22
Our clients presented data on treatment of NASH using STAMTM model at the DDW2021 (May 21-23).
-
UPCOMING EVENTS
2021.06.08
We are pleased to announce the acceptance of our abstract, “RNA-seq Analysis of Liver from Diabetic and NASH Model Mouse Treated with Streptozotocin, High-Fat Diet”, for presentation in the category “Integrated Physiology—Liver” at the 81st Annual Meeting of the American Diabetes Association, to be held from June 25 to 29, 2021.
-
UPCOMING EVENTS
Visit SMC Laboratories at BIO Digital 2021
2021.05.26
We are joining the world’s largest virtual biotech partnering and education event, convening thousands of global biotech leaders and innovators.
-
NEWS RELEASE
New Partnership with cancer model search service Repositive, Inc.
2021.05.21
SMC Laboratories, Inc. is pleased to announce a partnership with Repositive, Inc., a UK-based bespoke cancer model search service.
-
NEWS RELEASE
2021.05.12
Amplia Therapeutics, which is our client, has announced the results of pharmacology study using a STAM™ mouse model.
-
NEWS RELEASE
Chemomab announces enrollment of first patient in phase 2a study of CM-101 in NASH
2021.05.04
Chemomab Ltd.(Israel) announced on 26 April, 2021, enrollment of first patient in phase 2a study of CM-101 in NASH.
-
PRODUCTS AND SERVICES
Pre-clinical studies for cirrhosis: Carbon tetrachloride (CCl4)-induced liver fibrosis
2021.04.26
The CCl4-induced liver fibrosis model is a model that forms bridging fibrosis around the portal vein region.
